Skip to main content

Bard IVC Filter Plaintiff Produces Sufficient Evidence

Bard IVC Filter Plaintiff Produces Sufficient Evidence

Bard IVC Filter Plaintiff Produces Sufficient Evidence

Introduction

The U.S. District Court, District of Arizona was approached by C. R. Bard, the defendant named in the IVC Filter litigation involving the Eclipse filter, to pass a summary judgment for failure-to-warn, misrepresentation, negligence per se, consumer fraud and unfair trade practices, and punitive damages claims made by the plaintiff. As per the court order released in mid-March, the company’s motion to dismiss the plaintiffs’ failure-to-warn and punitive damage claims was rejected.

This would be the second bellwether IVC filter lawsuit which is scheduled to go before a jury on May 15, with a final pretrial conference planned for May 4.

About 3,000 IVC filter lawsuits are pending in the consolidated action against C.R. Bard for its Recovery, G2, G2 Express, G2X, Eclipse, Meridian, and Denali IVC filters wherein plaintiffs claim that due to manufacturing and design defects, Bard filters are more dangerous than other IVC filters and that Bard failed to warn about the higher risks.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!